Latest Breaking News On - Verge scientific communications - Page 3 : comparemela.com

Disc Medicine Receives FDA Orphan Drug Designation for DISC-3405 for the Treatment of ...

WATERTOWN, Mass., Feb. 09, 2024 (GLOBE NEWSWIRE) Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from

Werewolf Therapeutics Appoints Michael Atkins, M.D., to its Board of Directors

04.01.2024 - WATERTOWN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) - Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of novel, conditionally activated INDUKINE therapeutics .

4DMT and Arbor Biotechnologies Establish Partnership to Co-Develop and Co-Commercialize Next-Generation Genetic Medicines for CNS Diseases

Partnership brings together two leaders in next-generation genetic medicines to engineer, co-develop and co-commercialize AAV-delivered CRISPR/Cas-based therapeutics for up to six product candidates.

Disc Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference

WATERTOWN, Mass., Jan. 03, 2024 Disc Medicine, Inc. , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients.

Disc Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference